AR115575A1 - GREMLIN-1 ANTAGONIST FOR THE PREVENTION AND TREATMENT OF CANCER - Google Patents

GREMLIN-1 ANTAGONIST FOR THE PREVENTION AND TREATMENT OF CANCER

Info

Publication number
AR115575A1
AR115575A1 ARP190101686A ARP190101686A AR115575A1 AR 115575 A1 AR115575 A1 AR 115575A1 AR P190101686 A ARP190101686 A AR P190101686A AR P190101686 A ARP190101686 A AR P190101686A AR 115575 A1 AR115575 A1 AR 115575A1
Authority
AR
Argentina
Prior art keywords
cancer
prevention
treatment
antagonist
gremlin
Prior art date
Application number
ARP190101686A
Other languages
Spanish (es)
Inventor
Gareth Charles Glyndwr Davies
Simon Leedham
Andrew Zannettino
Kimberley Clark
Duncan Hewett
Vasilios Panagopoulos
Original Assignee
UCB Biopharma SRL
Univ Oxford Innovation Ltd
Univ Adelaide
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL, Univ Oxford Innovation Ltd, Univ Adelaide filed Critical UCB Biopharma SRL
Publication of AR115575A1 publication Critical patent/AR115575A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a un antagonista anti-GREM1 para uso en un método para el tratamiento o prevención de un cáncer.This refers to an anti-GREM1 antagonist for use in a method for the treatment or prevention of cancer.

ARP190101686A 2018-06-18 2019-06-18 GREMLIN-1 ANTAGONIST FOR THE PREVENTION AND TREATMENT OF CANCER AR115575A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1809946.5A GB201809946D0 (en) 2018-06-18 2018-06-18 Prevention and treatment of cancer

Publications (1)

Publication Number Publication Date
AR115575A1 true AR115575A1 (en) 2021-02-03

Family

ID=63042307

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190101686A AR115575A1 (en) 2018-06-18 2019-06-18 GREMLIN-1 ANTAGONIST FOR THE PREVENTION AND TREATMENT OF CANCER

Country Status (2)

Country Link
AR (1) AR115575A1 (en)
GB (1) GB201809946D0 (en)

Also Published As

Publication number Publication date
GB201809946D0 (en) 2018-08-01

Similar Documents

Publication Publication Date Title
CO2020015923A2 (en) Gremlin-1 antagonist for the prevention and treatment of cancer
DOP2019000180A (en) INHIBITORS OF TGFß1 ISOFORM-SPECIFIC CONTEXT-PERMISIVES AND USE OF THE SAME
CO2021001912A2 (en) Anti-cd112r compositions and methods
CL2018002878A1 (en) Anti-tim-3 compositions and antibodies.
CL2018002012A1 (en) Maitansinoid derivatives, conjugates thereof and methods of use.
CL2018001512A1 (en) Humanized anti-CD73 antibodies.
CL2017002050A1 (en) Use of plinabulin in combination with immune control point inhibitors
BR112019005908A2 (en) use of anti-pd-1 antibody and vegfr inhibitor combination in cancer drug preparation
CL2016002027A1 (en) Cyclopropylamine as an inhibitor of lsd1
CO2019001193A2 (en) Methods and compositions for the treatment of epileptic disorders
CO2017005784A2 (en) Fused bicyclic compounds for the treatment of diseases
ECSP17018120A (en) TRIAZOLOPYRAZINONES AS PDE1 INHIBITORS
CL2018003444A1 (en) Adenosine derivatives for use in the treatment of cancer.
CO2017007121A2 (en) Fused bicyclic compounds for the treatment of diseases
BR112016017112A2 (en) APILIMOD COMPOSITIONS AND METHODS OF USE THEREOF
CO2018013020A2 (en) Pharmaceutical combinations for cancer treatment
CL2016003074A1 (en) Compounds derived from 2-oxy-2-phenyl-n-5-pyrrolidin-3-ylamino-1,3,4-thiadiazol-2-ylacetamide, pharmaceutical composition gls1 inhibitors and their use to treat cancer.
CL2016002151A1 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
ES2970224T3 (en) Tinostamustine for use in the treatment of sarcoma
BR112017009265A2 (en) apilimode for use in colorectal cancer treatment
AR104755A1 (en) METHOD FOR THE TREATMENT OF NEUROLOGICAL DISEASE
DK3463436T3 (en) VACCINE IN COMBINATION WITH AN IMMUNE CHECKPOINT INHIBITOR FOR USE IN THE TREATMENT OF CANCER
AR103119A1 (en) USE OF ELSIGLUTIDA TO TREAT GASTROINTESTINAL MUCOSITIS, INCLUDING DIARRHEA INDUCED BY CHEMOTHERAPY
CL2018002638A1 (en) Ambrisentan for use in the treatment of acute renal failure
ECSP16071574A (en) HEXAHYDROFUROPYRROLS AS PDE1 INHIBITORS